InvestorsHub Logo
Followers 32
Posts 10384
Boards Moderated 0
Alias Born 04/20/2016

Re: BAE44 post# 53656

Monday, 03/15/2021 1:38:25 PM

Monday, March 15, 2021 1:38:25 PM

Post# of 54032
Some people are certifiable. Most people have no idea how much money it takes or how many hoops the FDA puts you through just to begin a trial.

I bet the Company has spent nearly $1 mil so far on the pharma project.

In any event, I hoped it would have been green lighted by now and I think it will be in the first half of the year. There are quite a few drugs using CBD now in clinical trials. A company from Isreal just had a nausea drug approved, it is a huge market.

The retail gum should pay the bills and I like that the last CBD gum used upped the MG to 15mg although I would like to see 25mg, not sure how that effects taste and texture though. Unlike most other CBD products you know exactly what MG you are getting in each gum piece.

If you go way back you can read assanine comments like the CEO was in on the auditor malpractice, that he would never catch up on filings, that the lawsuit was worthless, that investing in BLNK and VTGN was stupid.

I would ignore any nonsense about patents, as TAUG has top level patent attorney and the same attorney working with the FDA that worked with Epidiolex to get approved. That is the same company that Jazz recently spent $7.1 billion on a buyout.

It would be ridiculous to have spent all the money on patents before knowing if the trial would be approved. The FDA looks into ingredient sourcing, manufacturing locations, processes and a littany of other things before a trial is allowed to move forward.

This is a high risk high reward play as far as pharma goes. But the trial is not to cure a disease, it is simply to alleviate nausea suffering patients have.

TAUG taking positive steps with the Board as well. Jim Rosati is quite accomplished.

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.